You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.
The study, led by researchers from precision health firm Human Longevity, also uncovered phenotypic evidence supporting some pathogenic genetic findings.
The oncology division of Human Longevity performs next-generation sequencing services for pharmaceutical customers and generated $10 million in revenue in 2019.
The San Diego-based company plans to use the proceeds from the financing to enhance its Health Nucleus intelligence platform.
A judge has dismissed a lawsuit brought by Human Longevity against the J. Craig Venter Institute.
Human Longevity had filed the suit in July, alleging the misappropriation of trade secrets by Craig Venter, who founded both the company and the institute.
The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.
The scientists developed a metabolomic panel capable of predicting BMI and identifying subsets of at-risk patients with apparently healthy BMIs.
A brief recap of Genetics/Genomics news the week of Aug 31, 2018: Perosnalize Medicine Coalition, Enzo Biochem, Hoosier Cancer Research Network, Scor Global Life, and ALCF
The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.
The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.
A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.
In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.